The carboxy-terminal region of human growth hormone (hGH) has attracted sustained scientific interest since investigators first demonstrated that a discrete 15-residue peptide, corresponding to amino acids 177–191, retains the lipolytic and antilipogenic properties of the intact 191-amino-acid protein. AOD9604—a modified analogue of this fragment bearing an N-terminal tyrosine substitution and an internal disulfide bridge—has since become one of the most extensively studied peptide tools for dissecting the molecular determinants of growth-hormone-mediated fat metabolism. This review examines the structural features, receptor pharmacology, and enzymatic targets that underpin AOD9604’s activity in preclinical adipocyte and animal models.
This article is provided for informational and research purposes only. AOD9604 is not approved for human or animal use and is sold strictly as a research chemical.
Historical Context: Mapping the Lipolytic Domain of hGH
Work by Wu and Ng in 1993 first established that a synthetic peptide comprising residues 177–191 of hGH exhibited antilipogenic activity “identical with that of the intact molecule” in rat adipose tissue explants, while lacking measurable growth-promoting or diabetogenic effects (Wu & Ng, 1993). Subsequent structure-activity campaigns at Monash University generated a library of analogues in which the native phenylalanine at position 177 was replaced with tyrosine, and the two cysteine residues at positions 182 and 189 were oxidized to form an intramolecular disulfide bond. The resulting 16-amino-acid cyclic peptide—designated AOD9604—displayed improved metabolic stability and oral bioavailability relative to the linear parent sequence (Ng et al., 2000; Heffernan et al., 2000).
NMR spectroscopy of AOD9604 in aqueous dimethyl sulfoxide revealed two type I β-turns at residues Ser8–Val9–Glu10–Gly11 and Ser12–Cys13–Gly14–Phe15, each preceded by loop-like structures. This constrained conformation closely recapitulates the spatial arrangement of the corresponding region in crystallographic models of full-length hGH, supporting the hypothesis that the C-terminal domain functions as a structurally autonomous lipolytic module within the larger hormone (Ogru et al., 2000).
Dual Enzymatic Targets: HSL Activation and ACC Inhibition
In isolated rat epididymal adipose tissue, AOD9604 (and its closely related precursor AOD9401) stimulates hormone-sensitive lipase (HSL) while simultaneously inhibiting acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo fatty acid synthesis (Ng et al., 2000b). This dual action—augmenting triglyceride hydrolysis and suppressing lipogenesis—mirrors the metabolic profile of intact hGH in adipocytes but occurs without engagement of the canonical growth hormone receptor (GHR) or induction of insulin-like growth factor 1 (IGF-1) signaling.
HSL is the principal diacylglycerol lipase in white adipose tissue, catalyzing the penultimate step in complete triacylglycerol mobilization (Althaher, 2022). GH Fragment 176-191, the unmodified parent peptide, shares this capacity to activate HSL, though AOD9604’s constrained cyclic architecture confers measurably greater potency in chronic dosing regimens. On the lipogenic side, ACC catalyzes the carboxylation of acetyl-CoA to malonyl-CoA—the committed step in fatty acid biosynthesis. In tissue homogenates from obese murine models, AOD9604 treatment reduced ACC activity and lowered the rate of glucose incorporation into lipid by approximately 22 percent (Heffernan et al., 2001).
β3-Adrenergic Receptor Signaling and Lipolytic Sensitivity
A pivotal 2001 study by Heffernan and colleagues examined the chronic effects of hGH and AOD9604 in both ob/ob obese mice and β3-adrenergic receptor (β3-AR) knockout mice. Both compounds reduced epididymal white adipose tissue mass and increased plasma glycerol—a systemic marker of lipolysis—in wild-type obese animals. Critically, these lipolytic effects were abolished in β3-AR-null mice, establishing the receptor as an obligate mediator of fragment-induced fat mobilization (Heffernan et al., 2001).
Quantitative RT-PCR analysis revealed that chronic AOD9604 administration upregulated β3-AR mRNA in white adipose tissue of obese mice to levels comparable with lean controls. This finding suggests that the fragment does not function as a direct β3-AR agonist but instead restores receptor expression that is characteristically suppressed in the obese phenotype, thereby re-sensitizing adipocytes to endogenous catecholamine-driven lipolysis.
Subsequent work has clarified the broader significance of β3-AR in adipocyte biology. Cero et al. (2021) demonstrated in primary human brown and beige adipocytes that β3-AR silencing abolished agonist-stimulated cAMP accumulation, lipolysis, and uncoupling protein 1 (UCP1)-mediated thermogenesis. Collins (2022) reviewed how β-adrenergic receptor signaling coordinates lipolysis, fatty acid oxidation, and adaptive thermogenesis across white, beige, and brown fat depots. These findings underscore why restoration of β3-AR expression by AOD9604 may amplify multiple downstream metabolic outputs beyond simple triglyceride hydrolysis.
All compounds discussed in this article are intended for research purposes only and are not for human consumption.
Independence from the Growth Hormone Receptor and IGF-1 Axis
A defining pharmacological feature of AOD9604 is its failure to bind or activate the GHR. Competitive binding assays confirm no displacement of radiolabeled hGH from hepatic or adipocyte GHR preparations, and chronic administration does not elevate circulating IGF-1 in rodent models (Ng et al., 2000b; Heffernan et al., 2001). This dissociation has significant implications for research design: it enables investigators to study the lipolytic arm of growth hormone biology in isolation, without the confounding anabolic, mitogenic, and insulin-antagonistic effects mediated through the JAK2-STAT5 pathway downstream of GHR.
Recent mechanistic work on intact growth hormone has further contextualized this distinction. Sharma et al. (2019) showed that GH-induced lipolysis in human adipocytes operates through the PPARγ–FSP27 axis: GH impairs PPARγ transcriptional activity via MEK/ERK signaling, downregulating the lipid-droplet coat protein FSP27 (CIDEC) and destabilizing lipid droplets. Huang et al. (2023) extended this model by identifying type 2 adipocyte subpopulations as preferential GH targets. Whether AOD9604 engages any component of the PPARγ–FSP27 cascade independently of GHR remains an open experimental question and represents a productive avenue for future investigation.
Metabolic Outcomes in Animal Models
Chronic oral or intraperitoneal administration of AOD9604 to diet-induced and genetically obese mice consistently reduces cumulative body weight gain, white and brown adipose tissue mass, and mean adipocyte diameter—from approximately 110 μm to 80 μm in Zucker fatty rats (Ng et al., 2000b). Heffernan et al. (2001b) reported increased whole-body fat oxidation, measured by indirect calorimetry, without changes in lean mass, food intake, or locomotor activity. Importantly, euglycemic-hyperinsulinemic clamp studies confirmed that AOD9604 did not impair insulin sensitivity or glucose disposal, in contrast to equimolar doses of intact hGH (Ng et al., 2000).
These metabolic characteristics have prompted exploration of MOTS-c and other mitochondria-derived peptides as complementary tools for studying energy expenditure pathways. Tesamorelin, a growth-hormone-releasing hormone analogue, offers yet another pharmacological lens through which researchers compare direct lipolytic stimulation (AOD9604) against indirect GH-axis activation.
Beyond Adipocytes: Chondroprotective Observations
An intriguing secondary finding in AOD9604 research involves cartilage biology. Kwon and Park (2015) reported that intra-articular injection of AOD9604, alone or combined with high-molecular-weight hyaluronic acid, promoted proteoglycan and collagen production in chondrocytes and reduced cartilage degeneration scores in a collagenase-induced rabbit osteoarthritis model. Combined AOD9604–HA treatment was more effective than either agent alone. While the mechanism linking a lipolytic peptide fragment to extracellular matrix biosynthesis in cartilage remains poorly characterized, these data have broadened the scope of AOD9604 research beyond metabolic biology.
Safety Profile and Analytical Detection
Comprehensive toxicological evaluation of AOD9604, including Ames mutagenicity testing, chromosomal aberration assays, and bone marrow micronucleus assays, has revealed no genotoxic activity. Chronic oral dosing in rats and cynomolgus monkeys produced no adverse findings at any tested dose level (Moré & Kenley, 2014). In human tolerability studies, AOD9604 displayed a safety profile “indistinguishable from placebo” without the hyperglycemia, insulin resistance, or fluid retention associated with full-length hGH administration.
Cox et al. (2015) developed validated LC-MS/MS methods for detecting AOD9604 and its metabolic fragments in biological matrices, characterizing rapid proteolytic degradation kinetics that are consistent with the peptide’s short plasma half-life and the protracted absorption profile observed after oral administration. Researchers using AOD9604 in cell culture or animal protocols should consult the Oath Research lab results and certificates of analysis to verify peptide identity and purity before initiating experiments.
AOD9604 and all peptides discussed herein are sold for laboratory research use only. They are not intended for human or animal consumption and should not be used for diagnostic or therapeutic purposes.
What is the primary structural difference between AOD9604 and native hGH fragment 176–191?
AOD9604 differs from the native sequence in two key respects: a tyrosine residue replaces phenylalanine at the N-terminal position (residue 177), and the two internal cysteine residues (positions 182 and 189) are oxidized to form a disulfide bridge, creating a constrained cyclic topology. This cyclization stabilizes two type I β-turns that recapitulate the conformation of the corresponding region in intact hGH, conferring improved metabolic stability and oral bioavailability.
Does AOD9604 activate the growth hormone receptor?
No. Competitive binding assays consistently show that AOD9604 does not displace hGH from the growth hormone receptor, and chronic administration does not elevate IGF-1 levels. This pharmacological independence allows researchers to study lipolytic signaling without confounding anabolic or insulin-antagonistic pathways.
Why are β3-adrenergic receptor knockout mice unresponsive to AOD9604?
Studies in β3-AR-null mice demonstrate that the receptor is an obligate mediator of AOD9604-induced lipolysis. The peptide does not appear to function as a direct β3-AR agonist; rather, it upregulates receptor mRNA expression in adipose tissue, restoring catecholamine sensitivity that is characteristically depressed in obese phenotypes.
What enzymes does AOD9604 target in adipocytes?
AOD9604 activates hormone-sensitive lipase (HSL), which catalyzes triglyceride and diacylglycerol hydrolysis, while inhibiting acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo fatty acid synthesis. This dual enzymatic action produces simultaneous increases in lipolysis and decreases in lipogenesis.
How does AOD9604 affect insulin sensitivity in preclinical models?
Unlike intact hGH, AOD9604 does not impair insulin sensitivity or glucose disposal in rodent models, as demonstrated by euglycemic-hyperinsulinemic clamp studies. This dissociation from the diabetogenic effects of full-length growth hormone is one of the peptide’s most pharmacologically distinctive features.
Has AOD9604 been studied outside of adipose tissue biology?
Yes. Kwon and Park (2015) reported that intra-articular AOD9604 promoted proteoglycan and collagen synthesis in chondrocytes and reduced cartilage degeneration in a rabbit osteoarthritis model. The mechanism underlying this chondroprotective activity is not yet well characterized and represents an active area of investigation.
What analytical methods are used to detect AOD9604 in biological samples?
LC-MS/MS-based methods validated by Cox et al. (2015) enable detection of AOD9604 and its proteolytic metabolites in biological matrices. The peptide undergoes rapid degradation with a short plasma half-life, and absorption from the gastrointestinal tract is more protracted than after intravenous injection. Researchers can verify peptide identity and purity through third-party certificates of analysis.
References
Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993;30(1):187-196. PubMed
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PubMed
Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-298. PubMed
Ogru E, Wilson JC, Heffernan M, et al. The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000;56(6):388-397. PubMed
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PubMed
Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PubMed
Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed
Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. Journal Link
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. PubMed
Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432. PubMed
Sharma VM, Vestergaard ET, Jessen N, et al. Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes. Am J Physiol Endocrinol Metab. 2019;316(1):E34-E42. PubMed
Kopchick JJ, Berryman DE, Puri V, Lee KY, Jørgensen JOL. The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nat Rev Endocrinol. 2020;16(3):135-146. PubMed
Curious about getting that bronzed look without basking in the sun? Melanotan I, a tanning peptide making waves in research circles, promises a stunning tan— but does this shortcut to sun-kissed skin come with hidden risks?
Discover how the oxytocin peptide, a remarkable neuropeptide, sparks bonding, social trust, and enhanced emotional wellbeing—making it a fascinating focus for ongoing research into mood and human connection. Explore why scientists are so captivated by oxytocins powerful effects on relationships and trust!
Discover how the anti-inflammatory power of KPV peptide can help your gut and skin heal effortlessly—while also supporting natural immunity. This remarkable alpha-msh-fragment works gently with your body, soothing inflammation and restoring balance for true, lasting healing.
Preventing infections from peptide injections isn’t complicated, but it requires consistent attention to detail. One contaminated injection can lead to serious complications ranging from local abscesses to life-threatening sepsis. Here’s exactly how to protect yourself through proper sterile technique. Important: All peptides referenced in this article are intended strictly for in vitro research and laboratory …
AOD9604 and Lipolysis: Structure-Activity Relationships in the C-Terminal Fragment of Growth Hormone
The carboxy-terminal region of human growth hormone (hGH) has attracted sustained scientific interest since investigators first demonstrated that a discrete 15-residue peptide, corresponding to amino acids 177–191, retains the lipolytic and antilipogenic properties of the intact 191-amino-acid protein. AOD9604—a modified analogue of this fragment bearing an N-terminal tyrosine substitution and an internal disulfide bridge—has since become one of the most extensively studied peptide tools for dissecting the molecular determinants of growth-hormone-mediated fat metabolism. This review examines the structural features, receptor pharmacology, and enzymatic targets that underpin AOD9604’s activity in preclinical adipocyte and animal models.
This article is provided for informational and research purposes only. AOD9604 is not approved for human or animal use and is sold strictly as a research chemical.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Historical Context: Mapping the Lipolytic Domain of hGH
Work by Wu and Ng in 1993 first established that a synthetic peptide comprising residues 177–191 of hGH exhibited antilipogenic activity “identical with that of the intact molecule” in rat adipose tissue explants, while lacking measurable growth-promoting or diabetogenic effects (Wu & Ng, 1993). Subsequent structure-activity campaigns at Monash University generated a library of analogues in which the native phenylalanine at position 177 was replaced with tyrosine, and the two cysteine residues at positions 182 and 189 were oxidized to form an intramolecular disulfide bond. The resulting 16-amino-acid cyclic peptide—designated AOD9604—displayed improved metabolic stability and oral bioavailability relative to the linear parent sequence (Ng et al., 2000; Heffernan et al., 2000).
NMR spectroscopy of AOD9604 in aqueous dimethyl sulfoxide revealed two type I β-turns at residues Ser8–Val9–Glu10–Gly11 and Ser12–Cys13–Gly14–Phe15, each preceded by loop-like structures. This constrained conformation closely recapitulates the spatial arrangement of the corresponding region in crystallographic models of full-length hGH, supporting the hypothesis that the C-terminal domain functions as a structurally autonomous lipolytic module within the larger hormone (Ogru et al., 2000).
Dual Enzymatic Targets: HSL Activation and ACC Inhibition
In isolated rat epididymal adipose tissue, AOD9604 (and its closely related precursor AOD9401) stimulates hormone-sensitive lipase (HSL) while simultaneously inhibiting acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo fatty acid synthesis (Ng et al., 2000b). This dual action—augmenting triglyceride hydrolysis and suppressing lipogenesis—mirrors the metabolic profile of intact hGH in adipocytes but occurs without engagement of the canonical growth hormone receptor (GHR) or induction of insulin-like growth factor 1 (IGF-1) signaling.
HSL is the principal diacylglycerol lipase in white adipose tissue, catalyzing the penultimate step in complete triacylglycerol mobilization (Althaher, 2022). GH Fragment 176-191, the unmodified parent peptide, shares this capacity to activate HSL, though AOD9604’s constrained cyclic architecture confers measurably greater potency in chronic dosing regimens. On the lipogenic side, ACC catalyzes the carboxylation of acetyl-CoA to malonyl-CoA—the committed step in fatty acid biosynthesis. In tissue homogenates from obese murine models, AOD9604 treatment reduced ACC activity and lowered the rate of glucose incorporation into lipid by approximately 22 percent (Heffernan et al., 2001).
β3-Adrenergic Receptor Signaling and Lipolytic Sensitivity
A pivotal 2001 study by Heffernan and colleagues examined the chronic effects of hGH and AOD9604 in both ob/ob obese mice and β3-adrenergic receptor (β3-AR) knockout mice. Both compounds reduced epididymal white adipose tissue mass and increased plasma glycerol—a systemic marker of lipolysis—in wild-type obese animals. Critically, these lipolytic effects were abolished in β3-AR-null mice, establishing the receptor as an obligate mediator of fragment-induced fat mobilization (Heffernan et al., 2001).
Quantitative RT-PCR analysis revealed that chronic AOD9604 administration upregulated β3-AR mRNA in white adipose tissue of obese mice to levels comparable with lean controls. This finding suggests that the fragment does not function as a direct β3-AR agonist but instead restores receptor expression that is characteristically suppressed in the obese phenotype, thereby re-sensitizing adipocytes to endogenous catecholamine-driven lipolysis.
Subsequent work has clarified the broader significance of β3-AR in adipocyte biology. Cero et al. (2021) demonstrated in primary human brown and beige adipocytes that β3-AR silencing abolished agonist-stimulated cAMP accumulation, lipolysis, and uncoupling protein 1 (UCP1)-mediated thermogenesis. Collins (2022) reviewed how β-adrenergic receptor signaling coordinates lipolysis, fatty acid oxidation, and adaptive thermogenesis across white, beige, and brown fat depots. These findings underscore why restoration of β3-AR expression by AOD9604 may amplify multiple downstream metabolic outputs beyond simple triglyceride hydrolysis.
All compounds discussed in this article are intended for research purposes only and are not for human consumption.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Independence from the Growth Hormone Receptor and IGF-1 Axis
A defining pharmacological feature of AOD9604 is its failure to bind or activate the GHR. Competitive binding assays confirm no displacement of radiolabeled hGH from hepatic or adipocyte GHR preparations, and chronic administration does not elevate circulating IGF-1 in rodent models (Ng et al., 2000b; Heffernan et al., 2001). This dissociation has significant implications for research design: it enables investigators to study the lipolytic arm of growth hormone biology in isolation, without the confounding anabolic, mitogenic, and insulin-antagonistic effects mediated through the JAK2-STAT5 pathway downstream of GHR.
Recent mechanistic work on intact growth hormone has further contextualized this distinction. Sharma et al. (2019) showed that GH-induced lipolysis in human adipocytes operates through the PPARγ–FSP27 axis: GH impairs PPARγ transcriptional activity via MEK/ERK signaling, downregulating the lipid-droplet coat protein FSP27 (CIDEC) and destabilizing lipid droplets. Huang et al. (2023) extended this model by identifying type 2 adipocyte subpopulations as preferential GH targets. Whether AOD9604 engages any component of the PPARγ–FSP27 cascade independently of GHR remains an open experimental question and represents a productive avenue for future investigation.
Metabolic Outcomes in Animal Models
Chronic oral or intraperitoneal administration of AOD9604 to diet-induced and genetically obese mice consistently reduces cumulative body weight gain, white and brown adipose tissue mass, and mean adipocyte diameter—from approximately 110 μm to 80 μm in Zucker fatty rats (Ng et al., 2000b). Heffernan et al. (2001b) reported increased whole-body fat oxidation, measured by indirect calorimetry, without changes in lean mass, food intake, or locomotor activity. Importantly, euglycemic-hyperinsulinemic clamp studies confirmed that AOD9604 did not impair insulin sensitivity or glucose disposal, in contrast to equimolar doses of intact hGH (Ng et al., 2000).
These metabolic characteristics have prompted exploration of MOTS-c and other mitochondria-derived peptides as complementary tools for studying energy expenditure pathways. Tesamorelin, a growth-hormone-releasing hormone analogue, offers yet another pharmacological lens through which researchers compare direct lipolytic stimulation (AOD9604) against indirect GH-axis activation.
Beyond Adipocytes: Chondroprotective Observations
An intriguing secondary finding in AOD9604 research involves cartilage biology. Kwon and Park (2015) reported that intra-articular injection of AOD9604, alone or combined with high-molecular-weight hyaluronic acid, promoted proteoglycan and collagen production in chondrocytes and reduced cartilage degeneration scores in a collagenase-induced rabbit osteoarthritis model. Combined AOD9604–HA treatment was more effective than either agent alone. While the mechanism linking a lipolytic peptide fragment to extracellular matrix biosynthesis in cartilage remains poorly characterized, these data have broadened the scope of AOD9604 research beyond metabolic biology.
Safety Profile and Analytical Detection
Comprehensive toxicological evaluation of AOD9604, including Ames mutagenicity testing, chromosomal aberration assays, and bone marrow micronucleus assays, has revealed no genotoxic activity. Chronic oral dosing in rats and cynomolgus monkeys produced no adverse findings at any tested dose level (Moré & Kenley, 2014). In human tolerability studies, AOD9604 displayed a safety profile “indistinguishable from placebo” without the hyperglycemia, insulin resistance, or fluid retention associated with full-length hGH administration.
Cox et al. (2015) developed validated LC-MS/MS methods for detecting AOD9604 and its metabolic fragments in biological matrices, characterizing rapid proteolytic degradation kinetics that are consistent with the peptide’s short plasma half-life and the protracted absorption profile observed after oral administration. Researchers using AOD9604 in cell culture or animal protocols should consult the Oath Research lab results and certificates of analysis to verify peptide identity and purity before initiating experiments.
AOD9604 and all peptides discussed herein are sold for laboratory research use only. They are not intended for human or animal consumption and should not be used for diagnostic or therapeutic purposes.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Frequently Asked Questions
What is the primary structural difference between AOD9604 and native hGH fragment 176–191?
AOD9604 differs from the native sequence in two key respects: a tyrosine residue replaces phenylalanine at the N-terminal position (residue 177), and the two internal cysteine residues (positions 182 and 189) are oxidized to form a disulfide bridge, creating a constrained cyclic topology. This cyclization stabilizes two type I β-turns that recapitulate the conformation of the corresponding region in intact hGH, conferring improved metabolic stability and oral bioavailability.
Does AOD9604 activate the growth hormone receptor?
No. Competitive binding assays consistently show that AOD9604 does not displace hGH from the growth hormone receptor, and chronic administration does not elevate IGF-1 levels. This pharmacological independence allows researchers to study lipolytic signaling without confounding anabolic or insulin-antagonistic pathways.
Why are β3-adrenergic receptor knockout mice unresponsive to AOD9604?
Studies in β3-AR-null mice demonstrate that the receptor is an obligate mediator of AOD9604-induced lipolysis. The peptide does not appear to function as a direct β3-AR agonist; rather, it upregulates receptor mRNA expression in adipose tissue, restoring catecholamine sensitivity that is characteristically depressed in obese phenotypes.
What enzymes does AOD9604 target in adipocytes?
AOD9604 activates hormone-sensitive lipase (HSL), which catalyzes triglyceride and diacylglycerol hydrolysis, while inhibiting acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo fatty acid synthesis. This dual enzymatic action produces simultaneous increases in lipolysis and decreases in lipogenesis.
How does AOD9604 affect insulin sensitivity in preclinical models?
Unlike intact hGH, AOD9604 does not impair insulin sensitivity or glucose disposal in rodent models, as demonstrated by euglycemic-hyperinsulinemic clamp studies. This dissociation from the diabetogenic effects of full-length growth hormone is one of the peptide’s most pharmacologically distinctive features.
Has AOD9604 been studied outside of adipose tissue biology?
Yes. Kwon and Park (2015) reported that intra-articular AOD9604 promoted proteoglycan and collagen synthesis in chondrocytes and reduced cartilage degeneration in a rabbit osteoarthritis model. The mechanism underlying this chondroprotective activity is not yet well characterized and represents an active area of investigation.
What analytical methods are used to detect AOD9604 in biological samples?
LC-MS/MS-based methods validated by Cox et al. (2015) enable detection of AOD9604 and its proteolytic metabolites in biological matrices. The peptide undergoes rapid degradation with a short plasma half-life, and absorption from the gastrointestinal tract is more protracted than after intravenous injection. Researchers can verify peptide identity and purity through third-party certificates of analysis.
References
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
Melanotan I: Stunning Tanning Peptide or Risky Hype?
Curious about getting that bronzed look without basking in the sun? Melanotan I, a tanning peptide making waves in research circles, promises a stunning tan— but does this shortcut to sun-kissed skin come with hidden risks?
Oxytocin Peptide: Stunning Mood & Social Bonding Benefits
Discover how the oxytocin peptide, a remarkable neuropeptide, sparks bonding, social trust, and enhanced emotional wellbeing—making it a fascinating focus for ongoing research into mood and human connection. Explore why scientists are so captivated by oxytocins powerful effects on relationships and trust!
KPV Peptide: Powerful Anti-Inflammatory for Effortless Gut & Skin Healing
Discover how the anti-inflammatory power of KPV peptide can help your gut and skin heal effortlessly—while also supporting natural immunity. This remarkable alpha-msh-fragment works gently with your body, soothing inflammation and restoring balance for true, lasting healing.
How to Prevent Infection from Peptide Injections
Preventing infections from peptide injections isn’t complicated, but it requires consistent attention to detail. One contaminated injection can lead to serious complications ranging from local abscesses to life-threatening sepsis. Here’s exactly how to protect yourself through proper sterile technique. Important: All peptides referenced in this article are intended strictly for in vitro research and laboratory …